These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 769959)

  • 41. A pilot study of sequential combination chemotherapy with adriamycin and cyclophosphamide, and methotrexate, 5-fluorouracil and prednisolone in advanced breast cancer.
    Collis CH
    Br J Clin Pract; 1978 May; 32(5):139-44. PubMed ID: 666968
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of adenocarcinoma with combinations of cyclopjosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
    Tucker WG; Talley RW; Lane M; Bonnet JD
    Cancer Chemother Rep; 1975; 59(2 Pt 1):425-7. PubMed ID: 1097101
    [No Abstract]   [Full Text] [Related]  

  • 43. Adriamycin therapy for advanced insulinoma.
    Eastman RC; Come SE; Strewler GJ; Gorden P; Kahn CR
    J Clin Endocrinol Metab; 1977 Jan; 44(1):142-8. PubMed ID: 188859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alternating administration of adriamycin (NSC-123127) and vincristine (NSC-67574)-actinomycin D (NSC-3053) in advanced sarcomas.
    Douglass HO; Karakousis C
    Cancer Chemother Rep; 1975; 59(5):1045-7. PubMed ID: 1106847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-day iv infusion with 5-fluorouracil (5-FU; NSC-19893) for gastroenteric carcinoma after failure on weekly 5-FU therapy.
    Hum GJ; Bateman JR
    Cancer Chemother Rep; 1975; 59(6):1171-9. PubMed ID: 769960
    [No Abstract]   [Full Text] [Related]  

  • 46. Response and survival of patients with metastatic neuroblastoma after combination chemotherapy with adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
    Gasparini M; Bellani FF; Musumeci R; Bonadonna G
    Cancer Chemother Rep; 1974; 58(3):365-70. PubMed ID: 4601666
    [No Abstract]   [Full Text] [Related]  

  • 47. [Efficacy of combined chemotherapy with nedaplatin, adriamycin, and 5-FU (NAF), and clinical factors affecting its effect in patients with advanced esophageal cancer].
    Hasegawa H; Fujitani K; Hirao M; Nakazuru S; Mita E; Tsujinaka T
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2591-5. PubMed ID: 22189224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
    Rocca A; Maltoni R; Passardi A; Massa I; Aquilina M; Ridolfi R; Ibrahim T; Cecconetto L; Sarti S; Pietri E; Nanni O; Amadori D
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):871-6. PubMed ID: 19693503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study.
    Friedman MA; Volberding PA; Cassidy MJ; Resser KJ; Wasserman TH; Phillips TL
    Cancer Treat Rep; 1979; 63(11-12):1885-8. PubMed ID: 230895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil.
    Robinson MR; Smith PH; Macaluso MP; Mulder JH; Martínez-Pinéiro JA; Cifuentes-Delatte L; Bono A; Glashan RW
    Eur Urol; 1977; 3(5):276-8. PubMed ID: 913456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas.
    Bonomi PD; Slayton RE; Wolter J
    Cancer Treat Rep; 1978 Aug; 62(8):1211-3. PubMed ID: 356979
    [No Abstract]   [Full Text] [Related]  

  • 52. Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
    Dalley DN; Levi JA; Aroney RS
    Med J Aust; 1980 Mar; 1(5):216-8. PubMed ID: 6990214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of advanced stomach carcinoma with adriamycin and 5-fluorouracil].
    Pérez JE; Macchiavelli M; Leone BA; Romero A; Rabinovich MG; Arévalo E; Strauss E
    Acta Gastroenterol Latinoam; 1984; 14(1):63-72. PubMed ID: 6524270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A randomized clinical trial of cyclophosphamide versus adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate in advanced ovarian carcinoma--a preliminary report ].
    Chylak V; Ilijas M; Krusić J; Kolarić K
    Lijec Vjesn; 1982; 104(3-4):120-2. PubMed ID: 6750298
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma.
    Sieper WJ; Mastrangelo MJ; Belle RE
    Cancer Chemother Rep; 1975; 59(6):1181-2. PubMed ID: 769962
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil.
    Rosenthal MA; Gibbs P; Brown TJ; Wong S; Uren S; Ellis A; Li L; Heldin P; Fox RM
    Chemotherapy; 2005 May; 51(2-3):132-41. PubMed ID: 15886473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program.
    Moore GE; Bross ID; Ausmans R; Nadler S; Jones R; Slack N; Rimm AA
    Cancer Chemother Rep; 1968 Oct; 52(6):641-53. PubMed ID: 4895427
    [No Abstract]   [Full Text] [Related]  

  • 58. 100% oxygen inhalation and 5-fluorouracil (NSC-19893) therapy for large bowel carcinoma.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1974; 58(6):951-2. PubMed ID: 4614903
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical aspects of adriamycin in Japan.
    Furue H; Komita T
    Recent Results Cancer Res; 1978; 63():247-51. PubMed ID: 705010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. On the reported lack of effectiveness of daunomycin (NSC-82151) and adriamycin (NSC-123127) on solid tumors.
    Lenaz L; Di Marco A
    Cancer Chemother Rep; 1972 Aug; 56(4):431-2. PubMed ID: 5081585
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.